Immatics N.V. Company Profile

Background

Immatics N.V. is a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies for cancer treatment. The company's mission is to harness the power of T cells to combat cancer, focusing on solid tumors through innovative therapeutic modalities. Immatics operates primarily in the biotechnology sector, contributing significantly to advancements in cancer immunotherapy.

Key Strategic Focus

Immatics concentrates on two main therapeutic approaches:

• Adoptive Cell Therapies (ACT): This includes both autologous and allogeneic TCR-engineered cell therapies designed to target specific cancer antigens.

• TCR Bispecifics (TCER): These are antibody-like molecules engineered to engage T cells and direct them to tumor cells expressing particular antigens.

The company's core objectives involve advancing these therapies through clinical development, leveraging proprietary technologies to identify novel cancer targets, and expanding their reach into various solid tumor indications.

Financials and Funding

Immatics has secured substantial funding to support its research and development initiatives. Notably:

• Business Combination and NASDAQ Listing (July 2020): Immatics completed a business combination with Arya Sciences Acquisition Corp., a special purpose acquisition company sponsored by Perceptive Advisors. This transaction resulted in gross proceeds of approximately $253 million, combining funds from Arya's trust account and a concurrent PIPE financing.

• Public Offering (2024): The company announced a $150 million public offering to further bolster its financial position and support ongoing and future projects.

These funds are primarily allocated to advancing clinical trials, expanding manufacturing capabilities, and supporting operational growth.

Pipeline Development

Immatics' pipeline features several promising candidates:

• IMA203: A TCR-T cell therapy targeting PRAME, a protein frequently expressed in various solid tumors. IMA203 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for multiple indications, including cutaneous and uveal melanoma, endometrial carcinoma, synovial sarcoma, and ovarian cancer.

• IMA203CD8: An enhanced version of IMA203, currently in Phase 1b clinical trials, designed to improve T cell engagement and efficacy.

• IMA204: A preclinical candidate targeting tumor stroma, aiming to disrupt the tumor microenvironment and enhance immune response.

• IMA30x: An allogeneic cellular therapy product candidate in preclinical development, representing a potential "off-the-shelf" solution for cancer treatment.

• IMA401 and IMA402: TCR Bispecifics targeting MAGEA4/8, with IMA401 having presented clinical proof-of-concept data from an ongoing Phase 1 dose escalation trial.

Technological Platform and Innovation

Immatics distinguishes itself through proprietary technologies and methodologies:

• XPRESIDENT® Platform: A mass spectrometry-based target discovery platform that identifies true cancer targets by analyzing the immunopeptidome of tumor and normal tissues.

• XCEPTOR® Platform: A TCR discovery and engineering platform that generates highly specific T cell receptors against identified targets, enhancing the precision and efficacy of TCR-based therapies.

• ACTengine®: A personalized cell therapy approach where a patient's own T cells are genetically modified to express a novel TCR targeting a specific cancer antigen.

• ACTallo®: An allogeneic cell therapy platform under development, aiming to create "off-the-shelf" TCR-T products for broader patient accessibility.

Leadership Team

Immatics is led by a team of experienced professionals:

• Dr. Harpreet Singh, Ph.D. – Chief Executive Officer and Managing Director.

• Dr. Toni Weinschenk, Ph.D. – Co-Founder and Chief Innovation Officer.

• Mr. Arnd Christ, MBA – Chief Financial Officer.

• Dr. Carsten Reinhardt, M.D., Ph.D. – Chief Development Officer.

• Dr. Steffen Walter, Ph.D. – Chief Operations Officer.

• Dr. Cedrik M. Britten, M.D. – Chief Medical Officer.

• Mr. Edward A. Sturchio, J.D. – General Counsel and Secretary.

• Mr. Jordan Silverstein – Head of Strategy.

Leadership Changes

In July 2024, Immatics appointed Alise Reicin to its Board of Directors, bringing additional expertise to the company's leadership.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in cancer immunotherapy, is experiencing significant growth. The global market for T cell therapies is expanding rapidly, driven by advancements in personalized medicine and increasing demand for effective cancer treatments.

Competitor Analysis

Immatics operates in a competitive landscape with several key players:

• Immunocore: Specializes in TCR-based therapies, focusing on soluble TCRs fused to an anti-CD3 effector function.

• Adaptimmune: Develops TCR-engineered T cell therapies targeting solid tumors, with a pipeline that includes candidates in various stages of clinical development.

• Autolus: Focuses on next-generation CAR-T cell therapies for hematological malignancies and solid tumors.

• Eureka Therapeutics: Engages in the discovery of novel antibody immunotherapies for cancer treatment.

• Tessa Therapeutics: A clinical-stage biotechnology company developing cell therapies for cancer treatment.

Strategic Collaborations and Partnerships

Immatics has established significant collaborations to enhance its research and development capabilities:

• MD Anderson Cancer Center: A strategic collaboration to develop multiple T cell and TCR-based adoptive cellular therapies.

• Celgene Corporation: A partnership focused on developing novel adoptive cell therapies targeting multiple cancers.

• Genmab A/S: A collaboration to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

• UTHealth: An extended collaboration providing exclusive access to state-of-the-art cGMP manufacturing infrastructure at The Evelyn H.